Clinical Trial Update: Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GR-MD-02 for liver fibrosis in NASH with advanced fibrosis has completed successfully and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• GR-MD-02 (GR-MD-02)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-09-28